TABLE 1 | Key late-stage (Phase III) antibacterial drugs in development
From the following article:
The antibacterial drugs market
Hedwig Kresse, Mark J. Belsey and Holger Rovini
Nature Reviews Drug Discovery 6, 19-20 (January 2007)
doi:10.1038/nrd2226
| Compound | Class | Company | Indication |
|---|---|---|---|
| Doripenem | Carbapenem | Peninsula/Johnson&Johnson | HAP/VAP, cUTIs, cIAIs |
| Dalbavancin | Glycopeptide | Vicuron/Pfizer | cSSSIs |
| Ceftobiprole (BAL5788) | Cephalosporin | Basilea/Johnson&Johnson | cSSSIs /HAP |
| Cethromycin | Ketolide | Advanced Life Sciences | CAP, other RTIs |
| Telavancin | Glycopeptide | Theravance/Astellas | cSSSIs/HAP |
| Iclaprim | DHFR inhibitor | Arpida | cSSSIs |
| CAP, community-acquired pneumonia; cIAIs, complicated intra-abdominal infections; cSSSIs, complicated skin and skin structure infections; cUTI, complicated urinary-tract infections; DHFR, dihydrofolate reductase; HAP, hospital-acquired pneumonia; RTIs, respiratory-tract infections; VAP, ventilator-associated pneumonia. | |||
Download file
If the slide opens in your browser, select "File > Save As" to save it.
